Skip to main content
Erschienen in: Breast Cancer Research 1/2013

01.02.2013 | Review

Tissue transglutaminase as a central mediator in inflammation-induced progression of breast cancer

verfasst von: Navneet Agnihotri, Santosh Kumar, Kapil Mehta

Erschienen in: Breast Cancer Research | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

TGM2 is a stress-responsive gene that encodes a multifunctional and structurally complex protein called tissue transglutaminase (abbreviated as TG2 or tTG). TGM2 expression is frequently upregulated during inflammation and wounding. Emerging evidence indicates that TGM2 expression is aberrantly upregulated in multiple cancer cell types, particularly those selected for resistance to chemotherapy and radiation therapy and those isolated from metastatic sites. It is becoming increasingly evident that chronic expression of TG2 in epithelial cancer cells initiates a complex series of signaling networks which contributes to the development of drug resistance and an invasive phenotype. For example, forced or basal high expression of TG2 in mammary epithelial cells is associated with activation of nuclear transcription factor-kappa B (NF-κB), Akt, focal adhesion kinase, and hypoxia-inducible factor. All of these changes are considered hallmarks of aggressive tumors. TG2 expression is able to induce the developmentally regulated program of epithelial-to-mesenchymal transition (EMT) and to confer cancer stem cell (CSC) traits in mammary epithelial cells; both EMT and CSCs have been implicated in cancer metastasis and resistance to standard therapies. Importantly, TG2 expression in tumor samples is associated with poor disease outcome, increased drug resistance, and increased incidence of metastasis. These observations imply that TG2 plays a crucial role in promoting an aggressive phenotype in mammary epithelial cells. In this review, we discuss recent evidence that TG2-regulated pathways contribute to the aggressive phenotype in breast cancer.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61: 69-90. 10.3322/caac.20107.CrossRefPubMed Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61: 69-90. 10.3322/caac.20107.CrossRefPubMed
2.
Zurück zum Zitat Radisky E, Radsky DC: Stromal induction of breast cancer: inflammation and invasion. Rev Endocr Metab Disord. 2007, 8: 279-287. 10.1007/s11154-007-9037-1.CrossRefPubMed Radisky E, Radsky DC: Stromal induction of breast cancer: inflammation and invasion. Rev Endocr Metab Disord. 2007, 8: 279-287. 10.1007/s11154-007-9037-1.CrossRefPubMed
3.
Zurück zum Zitat Mehta K, Kumar A, Kim HI: Transglutaminase 2: a multi-tasking protein in the complex circuitry of inflammation and cancer. Biochem Pharmacol. 2010, 80: 1921-1929. 10.1016/j.bcp.2010.06.029.CrossRefPubMed Mehta K, Kumar A, Kim HI: Transglutaminase 2: a multi-tasking protein in the complex circuitry of inflammation and cancer. Biochem Pharmacol. 2010, 80: 1921-1929. 10.1016/j.bcp.2010.06.029.CrossRefPubMed
4.
Zurück zum Zitat Lorand L, Graham RM: Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat Rev Mol Cell Biol. 2003, 4: 140-156. 10.1038/nrm1014.CrossRefPubMed Lorand L, Graham RM: Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat Rev Mol Cell Biol. 2003, 4: 140-156. 10.1038/nrm1014.CrossRefPubMed
5.
Zurück zum Zitat Kiraly R, Demeny M, Fesus L: Protein transamidation by transglutaminase 2 in cells: a disputed Ca2+-dependent action of a multifunctional protein. FEBS J. 2011, 278: 4717-4739. 10.1111/j.1742-4658.2011.08345.x.CrossRefPubMed Kiraly R, Demeny M, Fesus L: Protein transamidation by transglutaminase 2 in cells: a disputed Ca2+-dependent action of a multifunctional protein. FEBS J. 2011, 278: 4717-4739. 10.1111/j.1742-4658.2011.08345.x.CrossRefPubMed
7.
Zurück zum Zitat Verma A, Mehta K: Tissue transglutaminase-mediated chemoresistance in cancer cells. Drug Resist Updat. 2007, 10: 144-151. 10.1016/j.drup.2007.06.002.CrossRefPubMed Verma A, Mehta K: Tissue transglutaminase-mediated chemoresistance in cancer cells. Drug Resist Updat. 2007, 10: 144-151. 10.1016/j.drup.2007.06.002.CrossRefPubMed
8.
Zurück zum Zitat Mehta K, Fok J, Miller FR, Koul D, Sahin AA: Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer. Clin Cancer Res. 2004, 10: 8068-8076. 10.1158/1078-0432.CCR-04-1107.CrossRefPubMed Mehta K, Fok J, Miller FR, Koul D, Sahin AA: Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer. Clin Cancer Res. 2004, 10: 8068-8076. 10.1158/1078-0432.CCR-04-1107.CrossRefPubMed
9.
Zurück zum Zitat Mangala LS, Fok Y, Zorrilla-Calancha IR, Verma A, Mehta K: Tissue transglutaminase expression promotes cell attachment, invasion and survival in breast cancer cells. Oncogene. 2007, 26: 2459-2470. 10.1038/sj.onc.1210035.CrossRefPubMed Mangala LS, Fok Y, Zorrilla-Calancha IR, Verma A, Mehta K: Tissue transglutaminase expression promotes cell attachment, invasion and survival in breast cancer cells. Oncogene. 2007, 26: 2459-2470. 10.1038/sj.onc.1210035.CrossRefPubMed
10.
Zurück zum Zitat Oh K, Ko E, Kim HS, Park AK, Moon HG, Noh DY, Lee DS: Transglutaminase 2 facilitates the distant hematogenous metastasis of breast cancer by modulating interleukin-6 in cancer cells. Breast Cancer Res. 2011, 13: R96-10.1186/bcr3034.CrossRefPubMedPubMedCentral Oh K, Ko E, Kim HS, Park AK, Moon HG, Noh DY, Lee DS: Transglutaminase 2 facilitates the distant hematogenous metastasis of breast cancer by modulating interleukin-6 in cancer cells. Breast Cancer Res. 2011, 13: R96-10.1186/bcr3034.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Chekhun VF, Lukyanova NY, Kovalchuk O, Tryndyak VP, Pogribny IP: Epigenetic profiling of multidrugresistant human MCF-7 breast adenocarcinoma cells reveals novel hyper and hypomethylated targets. Mol Cancer Ther. 2007, 6: 1089-1098. 10.1158/1535-7163.MCT-06-0663.CrossRefPubMed Chekhun VF, Lukyanova NY, Kovalchuk O, Tryndyak VP, Pogribny IP: Epigenetic profiling of multidrugresistant human MCF-7 breast adenocarcinoma cells reveals novel hyper and hypomethylated targets. Mol Cancer Ther. 2007, 6: 1089-1098. 10.1158/1535-7163.MCT-06-0663.CrossRefPubMed
12.
Zurück zum Zitat Ai L, Kim WJ, Demircan B, Dyer LM, Bray KJ, Skehan RR, Massoll NA, Brown KD: The transglutaminase 2 gene (TGM2), a potential molecular marker for chemotherapeutic drug sensitivity, is epigenetically silenced in breast cancer. Carcinogenesis. 2008, 29: 510-518.CrossRefPubMed Ai L, Kim WJ, Demircan B, Dyer LM, Bray KJ, Skehan RR, Massoll NA, Brown KD: The transglutaminase 2 gene (TGM2), a potential molecular marker for chemotherapeutic drug sensitivity, is epigenetically silenced in breast cancer. Carcinogenesis. 2008, 29: 510-518.CrossRefPubMed
13.
Zurück zum Zitat Li B, Antonyak MA, Druso JE, Cheng L, Nikitin AY, Cerione RA: EGF potentiated oncogenesis requires a tissue transglutaminase-dependent signaling pathway leading to Src activation. Proc Natl Acad Sci USA. 2010, 107: 1408-1413. 10.1073/pnas.0907907107.CrossRefPubMedPubMedCentral Li B, Antonyak MA, Druso JE, Cheng L, Nikitin AY, Cerione RA: EGF potentiated oncogenesis requires a tissue transglutaminase-dependent signaling pathway leading to Src activation. Proc Natl Acad Sci USA. 2010, 107: 1408-1413. 10.1073/pnas.0907907107.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Wang Y, Ande SR, Mishra S: Phosphorylation of transglutaminase 2 (TG2) at serine-216 plays a role in TG2 mediated activation of nuclear factor-kappa B and in the downregulation of PTEN. BMC Cancer. 2012, 12: 277-10.1186/1471-2407-12-277.CrossRefPubMedPubMedCentral Wang Y, Ande SR, Mishra S: Phosphorylation of transglutaminase 2 (TG2) at serine-216 plays a role in TG2 mediated activation of nuclear factor-kappa B and in the downregulation of PTEN. BMC Cancer. 2012, 12: 277-10.1186/1471-2407-12-277.CrossRefPubMedPubMedCentral
15.
16.
Zurück zum Zitat Thiery JP, Acloque H, Huang RY, Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell. 2009, 139: 871-887. 10.1016/j.cell.2009.11.007.CrossRefPubMed Thiery JP, Acloque H, Huang RY, Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell. 2009, 139: 871-887. 10.1016/j.cell.2009.11.007.CrossRefPubMed
17.
Zurück zum Zitat Sarrio D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, Palacios J: Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res. 2008, 68: 989-997. 10.1158/0008-5472.CAN-07-2017.CrossRefPubMed Sarrio D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, Palacios J: Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res. 2008, 68: 989-997. 10.1158/0008-5472.CAN-07-2017.CrossRefPubMed
18.
Zurück zum Zitat Geradts J, de Herreros AG, Su Z, Burchette J, Broadwater G, Bachelder RE: Nuclear Snail1 and nuclear ZEB1 protein expression in invasive and intraductal human breast carcinomas. Hum Pathol. 2011, 42: 1125-1131. 10.1016/j.humpath.2010.11.004.CrossRefPubMedPubMedCentral Geradts J, de Herreros AG, Su Z, Burchette J, Broadwater G, Bachelder RE: Nuclear Snail1 and nuclear ZEB1 protein expression in invasive and intraductal human breast carcinomas. Hum Pathol. 2011, 42: 1125-1131. 10.1016/j.humpath.2010.11.004.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Kumar A, Xu J, Brady S, Gao H, Yu D, Reuben J, Mehta K: Tissue transglutaminase promotes drug resistance and invasion by inducing mesenchymal transition in mammary epithelial cells. PLoS One. 2010, 5: e13390-10.1371/journal.pone.0013390.CrossRefPubMedPubMedCentral Kumar A, Xu J, Brady S, Gao H, Yu D, Reuben J, Mehta K: Tissue transglutaminase promotes drug resistance and invasion by inducing mesenchymal transition in mammary epithelial cells. PLoS One. 2010, 5: e13390-10.1371/journal.pone.0013390.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Lacerda L, Pusztai L, Woodward WA: The role of tumor initiating cells in drug resistance of breast cancer: implications for future therapeutic approaches. Drug Resist Updat. 2010, 13: 99-108. 10.1016/j.drup.2010.08.001.CrossRefPubMed Lacerda L, Pusztai L, Woodward WA: The role of tumor initiating cells in drug resistance of breast cancer: implications for future therapeutic approaches. Drug Resist Updat. 2010, 13: 99-108. 10.1016/j.drup.2010.08.001.CrossRefPubMed
21.
Zurück zum Zitat Calcagno AM, Salcido CD, Gillet JP, Wu CP, Fostel JM, Mumau MD, Gottesman MM, Varticovski L, Ambudkar SV: Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. J Natl Cancer Inst. 2010, 102: 1637-1652. 10.1093/jnci/djq361.CrossRefPubMedPubMedCentral Calcagno AM, Salcido CD, Gillet JP, Wu CP, Fostel JM, Mumau MD, Gottesman MM, Varticovski L, Ambudkar SV: Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. J Natl Cancer Inst. 2010, 102: 1637-1652. 10.1093/jnci/djq361.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, Wong H, Rosen J, Chang JC: Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst. 2008, 100: 672-679. 10.1093/jnci/djn123.CrossRefPubMed Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, Wong H, Rosen J, Chang JC: Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst. 2008, 100: 672-679. 10.1093/jnci/djn123.CrossRefPubMed
23.
Zurück zum Zitat Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008, 133: 704-715. 10.1016/j.cell.2008.03.027.CrossRefPubMedPubMedCentral Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008, 133: 704-715. 10.1016/j.cell.2008.03.027.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Tham YL, Kalidas M, Elledge R, Mohsin S, Osborne CK, Chamness GC, Allred DC, Lewis MT, Wong H, O'Connell P: Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol. 2005, 23: 1169-1177. 10.1200/JCO.2005.03.156.CrossRefPubMed Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Tham YL, Kalidas M, Elledge R, Mohsin S, Osborne CK, Chamness GC, Allred DC, Lewis MT, Wong H, O'Connell P: Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol. 2005, 23: 1169-1177. 10.1200/JCO.2005.03.156.CrossRefPubMed
25.
Zurück zum Zitat Kumar A, Gao H, Xu J, Reuben J, Yu D, Mehta K: Evidence that aberrant expression of tissue transglutaminase promotes stem cell characteristics in mammary epithelial cells. PLoS One. 2011, 6: e20701-10.1371/journal.pone.0020701.CrossRefPubMedPubMedCentral Kumar A, Gao H, Xu J, Reuben J, Yu D, Mehta K: Evidence that aberrant expression of tissue transglutaminase promotes stem cell characteristics in mammary epithelial cells. PLoS One. 2011, 6: e20701-10.1371/journal.pone.0020701.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Kumar A, Xu J, Sung B, Kumar S, Yu D, Aggarwal BB, Mehta K: Evidence that GTP-binding domain but not catalytic domain of transglutaminase 2 is essential for epithelial-to-mesenchymal transition in mammary epithelial cells. Breast Cancer Res. 2012, 14: R4-10.1186/bcr3085.CrossRefPubMedPubMedCentral Kumar A, Xu J, Sung B, Kumar S, Yu D, Aggarwal BB, Mehta K: Evidence that GTP-binding domain but not catalytic domain of transglutaminase 2 is essential for epithelial-to-mesenchymal transition in mammary epithelial cells. Breast Cancer Res. 2012, 14: R4-10.1186/bcr3085.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Cao L, Shao M, Schilder J, Guise T, Mohammad KS, Matei D: Tissue transglutaminase links TGF-beta, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer. Oncogene. 2012, 31: 2521-2534. 10.1038/onc.2011.429.CrossRefPubMed Cao L, Shao M, Schilder J, Guise T, Mohammad KS, Matei D: Tissue transglutaminase links TGF-beta, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer. Oncogene. 2012, 31: 2521-2534. 10.1038/onc.2011.429.CrossRefPubMed
28.
29.
Zurück zum Zitat Ai L, Skehan RR, Saydi J, Lin T, Brown KD: Ataxia-Telangiectasia, Mutated (ATM)/Nuclear Factor κ light chain enhancer of activated B cells (NFκB) signaling controls basal and DNA damage-induced transglutaminase 2 expression. J Biol Chem. 2012, 287: 18330-18341. 10.1074/jbc.M112.339317.CrossRefPubMedPubMedCentral Ai L, Skehan RR, Saydi J, Lin T, Brown KD: Ataxia-Telangiectasia, Mutated (ATM)/Nuclear Factor κ light chain enhancer of activated B cells (NFκB) signaling controls basal and DNA damage-induced transglutaminase 2 expression. J Biol Chem. 2012, 287: 18330-18341. 10.1074/jbc.M112.339317.CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Ghanta KS, Pakala SB, Reddy SD, Li DQ, Nair SS, Kumar R: MTA1 coregulation of transglutaminase 2 expression and function during inflammatory response. J Biol Chem. 2011, 286: 7132-7138. 10.1074/jbc.M110.199273.CrossRefPubMed Ghanta KS, Pakala SB, Reddy SD, Li DQ, Nair SS, Kumar R: MTA1 coregulation of transglutaminase 2 expression and function during inflammatory response. J Biol Chem. 2011, 286: 7132-7138. 10.1074/jbc.M110.199273.CrossRefPubMed
31.
Zurück zum Zitat Kumar S, Mehta K: Tissue transglutaminase constitutively activates HIF-1α promoter and nuclear factor-κB via a non-canonical path. PLoS One. 2012, 7: e49321-10.1371/journal.pone.0049321.CrossRefPubMedPubMedCentral Kumar S, Mehta K: Tissue transglutaminase constitutively activates HIF-1α promoter and nuclear factor-κB via a non-canonical path. PLoS One. 2012, 7: e49321-10.1371/journal.pone.0049321.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Park KS, Kim DS, Jeong KC, Kim SY: Increase in transglutaminase 2 expression is associated with NF-kappaB activation in breast cancer tissues. Front Biosci. 2009, 14: 1945-1951.CrossRef Park KS, Kim DS, Jeong KC, Kim SY: Increase in transglutaminase 2 expression is associated with NF-kappaB activation in breast cancer tissues. Front Biosci. 2009, 14: 1945-1951.CrossRef
33.
Zurück zum Zitat Kim DS, Park SS, Nam BH, Kim IH, Kim SY: Reversal of drug resistance in breast cancer cells by transglutaminase 2 inhibition and nuclear factor-kappaB inactivation. Cancer Res. 2006, 66: 10936-10943. 10.1158/0008-5472.CAN-06-1521.CrossRefPubMed Kim DS, Park SS, Nam BH, Kim IH, Kim SY: Reversal of drug resistance in breast cancer cells by transglutaminase 2 inhibition and nuclear factor-kappaB inactivation. Cancer Res. 2006, 66: 10936-10943. 10.1158/0008-5472.CAN-06-1521.CrossRefPubMed
34.
Zurück zum Zitat Kim SY: Transglutaminase 2: a new paradigm for NF-kappaB involvement in disease. Adv Enzymol Relat Areas Mol Biol. 2011, 78: 161-195.PubMed Kim SY: Transglutaminase 2: a new paradigm for NF-kappaB involvement in disease. Adv Enzymol Relat Areas Mol Biol. 2011, 78: 161-195.PubMed
35.
Zurück zum Zitat Kim Y, Eom S, Kim K, Lee YS, Choe J, Hahn JH, Lee H, Kim YM, Ha KS, Ro JY, Jeoung D: Transglutaminase II interacts with rac1, regulates production of reactive oxygen species, expression of snail, secretion of Th2 cytokines and mediates in vitro and in vivo allergic inflammation. Mol Immunol. 2010, 47: 1010-1022. 10.1016/j.molimm.2009.11.017.CrossRefPubMed Kim Y, Eom S, Kim K, Lee YS, Choe J, Hahn JH, Lee H, Kim YM, Ha KS, Ro JY, Jeoung D: Transglutaminase II interacts with rac1, regulates production of reactive oxygen species, expression of snail, secretion of Th2 cytokines and mediates in vitro and in vivo allergic inflammation. Mol Immunol. 2010, 47: 1010-1022. 10.1016/j.molimm.2009.11.017.CrossRefPubMed
36.
Zurück zum Zitat Wilson WR, Hay MP: Targeting hypoxia in cancer therapy. Nat Rev Cancer. 2011, 11: 393-410. 10.1038/nrc3064.CrossRefPubMed Wilson WR, Hay MP: Targeting hypoxia in cancer therapy. Nat Rev Cancer. 2011, 11: 393-410. 10.1038/nrc3064.CrossRefPubMed
37.
Zurück zum Zitat Kim DS, Choi YB, Han BG, Park SY, Jeon Y, Kim DH, Ahn ER, Shin JE, Lee BI, Lee H, Hong KM, Kim SY: Cancer cells promote survival through depletion of the von Hippel-Lindau tumor suppressor by protein crosslinking. Oncogene. 2011, 30: 4780-4790. 10.1038/onc.2011.183.CrossRefPubMed Kim DS, Choi YB, Han BG, Park SY, Jeon Y, Kim DH, Ahn ER, Shin JE, Lee BI, Lee H, Hong KM, Kim SY: Cancer cells promote survival through depletion of the von Hippel-Lindau tumor suppressor by protein crosslinking. Oncogene. 2011, 30: 4780-4790. 10.1038/onc.2011.183.CrossRefPubMed
38.
Zurück zum Zitat Salgado R, Junius S, Benoy I, Van Dam P, Vermeulen P, Van Marck E, Huget P, Dirix LY: Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer. 2003, 103: 642-646. 10.1002/ijc.10833.CrossRefPubMed Salgado R, Junius S, Benoy I, Van Dam P, Vermeulen P, Van Marck E, Huget P, Dirix LY: Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer. 2003, 103: 642-646. 10.1002/ijc.10833.CrossRefPubMed
39.
Zurück zum Zitat Cieply B, Riley P 4th, Pifer PM, Widmeyer J, Addison JB, Ivanov AV, Denvir J, Frisch SM: Suppression of the epithelial-mesenchymal transition by Grainyhead-like-2. Cancer Res. 2012, 72: 2440-2453. 10.1158/0008-5472.CAN-11-4038.CrossRefPubMedPubMedCentral Cieply B, Riley P 4th, Pifer PM, Widmeyer J, Addison JB, Ivanov AV, Denvir J, Frisch SM: Suppression of the epithelial-mesenchymal transition by Grainyhead-like-2. Cancer Res. 2012, 72: 2440-2453. 10.1158/0008-5472.CAN-11-4038.CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Antonyak MA, Miller AM, Jansen JM, Boehm JE, Balkman CE, Wakshlag JJ, Page RL, Cerione RA: Augmentation of tissue transglutaminase expression and activation by epidermal growth factor inhibit doxorubicin induced apoptosis in human breast cancer cells. J Biol Chem. 2004, 279: 41461-41467. 10.1074/jbc.M404976200.CrossRefPubMed Antonyak MA, Miller AM, Jansen JM, Boehm JE, Balkman CE, Wakshlag JJ, Page RL, Cerione RA: Augmentation of tissue transglutaminase expression and activation by epidermal growth factor inhibit doxorubicin induced apoptosis in human breast cancer cells. J Biol Chem. 2004, 279: 41461-41467. 10.1074/jbc.M404976200.CrossRefPubMed
41.
Zurück zum Zitat Antonyak MA, Li B, Regan AD, Feng Q, Dusaban SS, Cerione RA: Tissue transglutaminase is an essential participant in the epidermal growth factor-stimulated signaling pathway leading to cancer cell migration and invasion. J Biol Chem. 2009, 284: 17914-17925. 10.1074/jbc.M109.013037.CrossRefPubMedPubMedCentral Antonyak MA, Li B, Regan AD, Feng Q, Dusaban SS, Cerione RA: Tissue transglutaminase is an essential participant in the epidermal growth factor-stimulated signaling pathway leading to cancer cell migration and invasion. J Biol Chem. 2009, 284: 17914-17925. 10.1074/jbc.M109.013037.CrossRefPubMedPubMedCentral
42.
Zurück zum Zitat Wang Y, Ande SR, Mishra S: Overexpression of phospho mutant forms of transglutaminase 2 downregulates epidermal growth factor receptor. Biochem Biophys Res Commun. 2012, 417: 251-255. 10.1016/j.bbrc.2011.11.094.CrossRefPubMed Wang Y, Ande SR, Mishra S: Overexpression of phospho mutant forms of transglutaminase 2 downregulates epidermal growth factor receptor. Biochem Biophys Res Commun. 2012, 417: 251-255. 10.1016/j.bbrc.2011.11.094.CrossRefPubMed
43.
Zurück zum Zitat Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, Fong SF, Csiszar K, Giaccia A, Weninger W, Yamauchi M, Gasser DL, Weaver VM: Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell. 2009, 139: 891-906. 10.1016/j.cell.2009.10.027.CrossRefPubMedPubMedCentral Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, Fong SF, Csiszar K, Giaccia A, Weninger W, Yamauchi M, Gasser DL, Weaver VM: Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell. 2009, 139: 891-906. 10.1016/j.cell.2009.10.027.CrossRefPubMedPubMedCentral
44.
Zurück zum Zitat Hwang JY, Mangala LS, Fok JY, Lin YG, Merritt WM, Spannuth WA, Nick AM, Fiterman DJ, Vivas-Mejia PE, Deavers MT, Coleman RL, Lopez-Berestein G, Mehta K, Sood AK: Clinical and biological significance of tissue transglutaminase in ovarian carcinoma. Cancer Res. 2008, 68: 5849-5858. 10.1158/0008-5472.CAN-07-6130.CrossRefPubMedPubMedCentral Hwang JY, Mangala LS, Fok JY, Lin YG, Merritt WM, Spannuth WA, Nick AM, Fiterman DJ, Vivas-Mejia PE, Deavers MT, Coleman RL, Lopez-Berestein G, Mehta K, Sood AK: Clinical and biological significance of tissue transglutaminase in ovarian carcinoma. Cancer Res. 2008, 68: 5849-5858. 10.1158/0008-5472.CAN-07-6130.CrossRefPubMedPubMedCentral
45.
Zurück zum Zitat Verma A, Guha S, Diagaradjane P, Kunnumakkara AB, Sanguino AM, Lopez-Berestein G, Sood AK, Aggarwal BB, Krishnan S, Gelovani JG, Mehta K: Therapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer. Clin Cancer Res. 2008, 14: 2476-2483. 10.1158/1078-0432.CCR-07-4529.CrossRefPubMed Verma A, Guha S, Diagaradjane P, Kunnumakkara AB, Sanguino AM, Lopez-Berestein G, Sood AK, Aggarwal BB, Krishnan S, Gelovani JG, Mehta K: Therapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer. Clin Cancer Res. 2008, 14: 2476-2483. 10.1158/1078-0432.CCR-07-4529.CrossRefPubMed
46.
Zurück zum Zitat Badarau E, Collighan RJ, Griffin M: Recent advances in the development of tissue transglutaminase (TG2) inhibitors. Amino Acids. 2013, 44: 119-127. 10.1007/s00726-011-1188-4.CrossRefPubMed Badarau E, Collighan RJ, Griffin M: Recent advances in the development of tissue transglutaminase (TG2) inhibitors. Amino Acids. 2013, 44: 119-127. 10.1007/s00726-011-1188-4.CrossRefPubMed
47.
Zurück zum Zitat Budillon A, Carbone C, Gennaro ED: Tissue transglutaminase: a new target to reverse cancer drug resistance. Amino Acids. 2013, 44: 63-72. 10.1007/s00726-011-1167-9.CrossRefPubMed Budillon A, Carbone C, Gennaro ED: Tissue transglutaminase: a new target to reverse cancer drug resistance. Amino Acids. 2013, 44: 63-72. 10.1007/s00726-011-1167-9.CrossRefPubMed
48.
Zurück zum Zitat Pinkas DM, Strop P, Brunger AT, Khosla C: Transglutaminase 2 undergoes a large conformational change upon activation. PLoS Biol. 2007, 5: e327-10.1371/journal.pbio.0050327.CrossRefPubMedPubMedCentral Pinkas DM, Strop P, Brunger AT, Khosla C: Transglutaminase 2 undergoes a large conformational change upon activation. PLoS Biol. 2007, 5: e327-10.1371/journal.pbio.0050327.CrossRefPubMedPubMedCentral
49.
Zurück zum Zitat Yuan L, Holmes TC, Watts RE, Khosla C, Broekelmann TJ, Mecham R, Zheng H, Izaguirre EW, Rich KM: Novel chemo-sensitizing agent, ERW1227B, impairs cellular motility and enhances cell death in glioblastomas. J Neurooncol. 2011, 103: 207-219. 10.1007/s11060-010-0379-2.CrossRefPubMed Yuan L, Holmes TC, Watts RE, Khosla C, Broekelmann TJ, Mecham R, Zheng H, Izaguirre EW, Rich KM: Novel chemo-sensitizing agent, ERW1227B, impairs cellular motility and enhances cell death in glioblastomas. J Neurooncol. 2011, 103: 207-219. 10.1007/s11060-010-0379-2.CrossRefPubMed
Metadaten
Titel
Tissue transglutaminase as a central mediator in inflammation-induced progression of breast cancer
verfasst von
Navneet Agnihotri
Santosh Kumar
Kapil Mehta
Publikationsdatum
01.02.2013
Verlag
BioMed Central
Erschienen in
Breast Cancer Research / Ausgabe 1/2013
Elektronische ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr3371

Weitere Artikel der Ausgabe 1/2013

Breast Cancer Research 1/2013 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.